QNRX Quoin Pharma: ערך חשבונאי למניה

Quoin Pharmaceuticals relies on robotic tissue analysis to accelerate releases, although it faces logistical risks and regulatory pressure. A monopoly in the treatment of Netherton syndrome ensures a steady flow of capital. The visualization of the book value per share confirms this data, with the metric reaching the level of 1.95, reflecting the real-time dynamics of the company's net assets.

Book value per share reflects the portion of net assets attributable to a single security, allowing for an assessment of the actual asset backing of investments after deducting all liabilities. By analyzing the historical book value per share chart, an investor confirms the fundamental stability of Quoin Pharmaceuticals (QNRX), which is supported by the non-cyclical demand for the treatment of rare dermatological pathologies and guaranteed insurance coverage.